Hualan Bio's Affiliate Receives IND Application Acceptance Notice for Pembrolizumab Injection from NMPA

Hualan Biological Engineering, Inc.: Its participating company, Hualan Genetic Engineering Co., Ltd., has received the "Acceptance Notice" from the National Medical Products Administration for the clinical trial application of the domestically produced drug registration of Pembrolizumab Injection. Currently, in China, no similar drugs have been approved for marketing apart from the original research drug.